Senzar Asset Management’s Teva Pharmaceuticals TEVA Stock Holding History

Senzar Asset Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-558,889	Closed	-$29.9M	–	44
2016 Q1	$29.9M	Sell	558,889 -722,300	-56%	-$42.4M	5.94%	4
2015 Q4	$84.1M	Buy	1,281,189 +66,695	+5%	+$4.12M	9.35%	3
2015 Q3	$68.6M	Buy	1,214,494 +336,997	+38%	+$21.9M	9.97%	3
2015 Q2	$51.9M	Buy	877,497 +326,300	+59%	+$20.1M	8.91%	2
2015 Q1	$34.3M	Buy	551,197 +320,300	+139%	+$18.6M	8.37%	3
2014 Q4	$13.3M	Sell	230,897 -337,499	-59%	-$18.8M	3.89%	6
2014 Q3	$30.6M	Buy	568,396 +77,400	+16%	+$4.1M	8.96%	3
2014 Q2	$25.7M	Buy	490,996 +50,596	+11%	+$2.59M	9.83%	1
2014 Q1	$23.3M	Buy	440,400 +95,100	+28%	+$4.4M	12.32%	3
2013 Q4	$13.8M	Buy	+345,300	New	+$13.6M	11.31%	2

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return

PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Senzar Asset Management's TEVA Position: Q2 2016 in Review

Senzar Asset Management sold out of Teva Pharmaceuticals (TEVA) in Q2 2016, closing a stake of 558,889 shares — an estimated $29.9M sold.

Senzar Asset Management first reported a position in TEVA in Q4 2013 and held it in 10 quarters. The position peaked at $84.1M in Q4 2015. 812 funds tracked by Wall St. Rank hold TEVA as of Q2 2016.

Senzar Asset Management reported no remaining Teva Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
Senzar Asset Management sold 558,889 Teva Pharmaceuticals shares in Q2 2016, an estimated $29.9M.
Senzar Asset Management first reported a position in Teva Pharmaceuticals in Q4 2013 and held it in 10 quarters.
Senzar Asset Management's Teva Pharmaceuticals position peaked at $84.1M in Q4 2015.
812 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2016.

Based on Senzar Asset Management's 13F filing for Q2 2016, filed 12 Aug 2016.